Menu
February 25, 2021  |  

Long-read genome sequencing for the diagnosis of neurodevelopmental disorders

Authors: Hiatt, Susan M. and Lawlor, James M.J. and Handley, Lori H. and Ramaker, Ryne C. and Rogers, Brianne B. and Partridge, E. Christopher and Boston, Lori Beth and Williams, Melissa and Plott, Christopher B. and Jenkins, Jerry and Gray, David E. and Holt, James M. and Bowling, Kevin M. and Bebin, E. Martina and Grimwood, Jane and Schmutz, Jeremy and Cooper, Gregory M.

Purpose Exome and genome sequencing have proven to be effective tools for the diagnosis of neurodevelopmental disorders (NDDs), but large fractions of NDDs cannot be attributed to currently detectable genetic variation. This is likely, at least in part, a result of the fact that many genetic variants are difficult or impossible to detect through typical short-read sequencing approaches.Methods Here, we describe a genomic analysis using Pacific Biosciences circular consensus sequencing (CCS) reads, which are both long (>10 kb) and accurate (>99% bp accuracy). We used CCS on six proband-parent trios with NDDs that were unexplained despite extensive testing, including genome sequencing with short reads.Results We identified variants and created de novo assemblies in each trio, with global metrics indicating these data sets are more accurate and comprehensive than those provided by short-read data. In one proband, we identified a likely pathogenic (LP), de novo L1-mediated insertion in CDKL5 that results in duplication of exon 3, leading to a frameshift. In a second proband, we identified multiple large de novo structural variants, including insertion-translocations affecting DGKB and MLLT3, which we show disrupt MLLT3 transcript levels. We consider this extensive structural variation likely pathogenic.Conclusion The breadth and quality of variant detection, coupled to finding variants of clinical and research interest in two of six probands with unexplained NDDs strongly support the value of long-read genome sequencing for understanding rare disease.Competing Interest StatementThe authors have declared no competing interest.

Journal: BioRxiv
DOI: 10.1101/2020.07.02.185447
Year: 2020

Read publication

Talk with an expert

If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.